Evaluation of the Hemodynamic Effect of Dexmedetomidine in Scheduled Outpatient Surgery

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Oct 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called dexmedetomidine compared to a common opioid, sufentanil, during outpatient surgeries. The goal is to see how well dexmedetomidine can help maintain stable blood flow and heart function when used for general anesthesia. This is particularly important because opioids can cause side effects like nausea, vomiting, and a longer recovery time. By exploring dexmedetomidine as an alternative, the researchers hope to find a safer option for patients undergoing less complex surgeries.

To participate in this trial, patients must be scheduled for certain types of surgeries, such as oral, orthopedic, or gynecological procedures, and they need to give their consent. However, certain individuals, like those with specific heart conditions, significant liver or kidney issues, or allergies to dexmedetomidine, won’t be eligible. If chosen to participate, patients can expect close monitoring during the surgery and to provide feedback on their recovery experience. This study is currently recruiting participants and aims to enhance the safety and comfort of outpatient surgical procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with scheduled surgery under general anesthesia for one of the following: oral, orthopedic, urological, digestive and gynecological surgeries.
• • The patient must have given their free and informed consent and signed the consent form
• • The patient must be a member or beneficiary of a health insurance plan
• Exclusion Criteria:
• • The subject is in a period of exclusion determined by a previous study
• • The subject is unable to give consent
• • It is impossible to give the subject informed information
• • The patient is under safeguard of justice or state guardianship
• • Patient with a known allergy to dexmedetomidine or other drugs.
• • Patient with a contraindication to general anesthesia or outpatient management.
• • Patient treated with beta-blocker, ACE inhibitor or ARB2
• • Patient with an ASA4 score.
• • Patient with HR \< 50 bpm.
• • Patient with the following cardiovascular comorbidities: coronary insufficiency, obstructive cardiomyopathy, severe hypertension, ventricular rhythm or conduction disorder.
• • Patient with hepatic (prothrombin rate \< 70%, liver enzyme/Bilirubin X 3) and/or renal (clearance \< 50 ml.min) insufficiency.
• • Pregnant, parturient or nursing patient